Monitoring Thyroid Function in Myxedema Coma
In myxedema coma, monitor thyroid function by measuring free T4 (not TSH) at baseline, then serially every 24-72 hours during acute treatment, with clinical response (mental status, heart rate, body temperature) being more important than biochemical normalization in the first 48-72 hours.
Initial Assessment
At presentation, obtain:
- Free T4 (typically severely low, but can be near-normal in some cases) 1
- TSH (usually markedly elevated, median >100 mIU/L) 2
- Free T3 (for baseline, though not essential for monitoring)
Critical caveat: Myxedema coma is a clinical diagnosis—do not delay treatment waiting for lab results. Biochemical hypothyroidism may be surprisingly mild despite profound clinical decompensation 1.
Acute Phase Monitoring (First 72 Hours)
Focus on clinical parameters over biochemical ones:
Clinical Response Markers (Check every 6-12 hours):
- Mental status improvement (Glasgow Coma Scale)
- Core body temperature normalization
- Heart rate increase (target >60 bpm)
- Blood pressure stabilization
- Respiratory function (CO2 clearance)
Biochemical Monitoring:
If using IV levothyroxine (500-1000 mcg loading dose):
- Free T4 peaks within 3 hours, reaching upper normal range 3
- T3 rises more gradually through peripheral conversion 3
- Do not chase supraphysiologic levels—clinical response occurs before biochemical normalization
If using oral levothyroxine (500 mcg day 1, then 100 mcg daily):
- Free T4 and T3 rise slowly, remaining in hypothyroid range initially 3
- Clinical improvement still occurs within 24-72 hours despite persistently low levels 3
- Oral absorption is variable but effective even with ileus 3
Post-Acute Monitoring (Days 3-14)
- Measure free T4 every 3-5 days
- Do not use TSH for monitoring during acute phase—it lags behind clinical and free T4 changes by weeks
- Continue daily clinical assessments of mental status, vital signs, and cardiac function
- Monitor for cardiac complications (arrhythmias, ischemia) with continuous telemetry 4
Transition to Maintenance Phase
Once clinically stable (typically 7-14 days):
- Switch to oral levothyroxine if not already done
- Check free T4 at 4-6 weeks after dose stabilization
- Only then begin monitoring TSH for long-term management 5
- Target TSH normalization over months, not days
Key Pitfalls to Avoid
- Don't wait for TSH normalization to assess treatment adequacy acutely—it's irrelevant in the first weeks
- Don't rely solely on biochemistry—a patient with "mild" TSH elevation (38 mIU/L) can still have true myxedema coma 1
- Don't over-treat based on labs—high IV doses cause supraphysiologic peaks but clinical response occurs with lower oral doses 3
- Don't forget adrenal coverage—always give hydrocortisone until adrenal insufficiency is ruled out, as thyroid hormone can precipitate adrenal crisis 5
- Monitor cardiac function closely—ventricular dysfunction is common (68% have impaired myocardial strain) and mortality can occur even with preserved ejection fraction 4
Practical Algorithm
Days 0-3: Free T4 at baseline → Clinical monitoring every 6-12 hours → Free T4 at 24-48 hours if no clinical improvement
Days 3-7: Free T4 every 3 days → Daily clinical assessments
Days 7-14: Free T4 twice weekly → Transition planning
Week 4-6: First TSH check after clinical stabilization on oral therapy
Ongoing: TSH every 6-12 months once stable 5